BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chai SY, Zhang RY, Ning ZY, Zheng YM, Swapnil R, Ji LN. Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis. World J Diabetes 2025; 16(7): 107335 [PMID: 40697602 DOI: 10.4239/wjd.v16.i7.107335]
URL: https://www.wjgnet.com/1948-9358/full/v16/i7/107335.htm
Number Citing Articles
1
Iuliana Popescu, Robert C. Bunn, Phil Ray, Kathryn M. Thrailkill, John L. Fowlkes. The SGLT2 Inhibitor Canagliflozin Promotes β‐Cell Regeneration and Restores and Stabilises β‐Cell Identity in a Polygenic Model of Severe Early‐Onset Type 2 DiabetesJournal of Cellular and Molecular Medicine 2026; 30(5) doi: 10.1111/jcmm.71041
2
Serafino Fazio, Flora Affuso. Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential HypertensionBiomedicines 2025; 13(12): 3102 doi: 10.3390/biomedicines13123102
3
Joseph A. M. J. L. Janssen. Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes—A Narrative ReviewInternational Journal of Molecular Sciences 2026; 27(5): 2150 doi: 10.3390/ijms27052150
4
Charlotte Delrue, Reinhart Speeckaert, Marijn M. Speeckaert. Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti-Aging TherapyInternational Journal of Molecular Sciences 2025; 26(19): 9372 doi: 10.3390/ijms26199372
5
Gaurab Bhaduri, Supratik Bhattacharyya, Shatavisa Mukherjee, Rutul Gokalani. Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative reviewActa Diabetologica 2026;  doi: 10.1007/s00592-025-02636-7